EC Nutrition

Obesity, driven by high caloric intake, poor nutrition, sedentary lifestyles, and genetic factors, affects over 1 billion people globally and has severe health consequences.

Recent advancements have introduced effective medications like GLP-1 agonists, including semaglutide (Ozempic/Wegovy), which show promise in reducing obesity-related complications.

Meal replacement protein shakes, providing balanced nutrients and high-quality proteins, can complement GLP-1 agonists, mitigating side effects and preserving muscle mass. Studies comparing semaglutide and meal replacement protein shakes reveal that the latter might produce similar or better weight reduction while maintaining lean mass.

Combining these approaches with lifestyle changes, including diet, exercise, stress management, and sleep improvement, could optimize obesity treatment and outcomes. This review emphasizes the potential synergy of combining GLP-1 agonists and meal replacement shakes, advocating for further research to validate these strategies and improve obesity management.

 Keywords: GLP1 Agonists; Meal Replacement; Obesity

1. Caballero B. “Humans against obesity: who will win?” Advances in Nutrition1 (2019): S4-S9.
2. Phelps NH., et al. “Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults”. The Lancet10431 (2024): 1027-1050.
3. Ryan DH., et al. “Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design”. American Heart Journal 229 (2020): 61-69.
4. Young GM., et al. “Medicare coverage and patient out-of-pocket costs for cardiovascular-kidney-metabolic medications”. JAMA Network Open5 (2024): e2412437.
5. Garvey WT., et al. “Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial”. Nature Medicine10 (2022): 2083-2091.
6. Ministério da Saúde Secretária de Vigilância Sanitária, do Ministério da Saúde Portaria No 30, de 13 de janeiro de 1998 (*). (n.d.).
7. Drucker DJ. “GLP-1 physiology informs the pharmacotherapy of obesity”. Molecular Metabolism 57 (2022): 101351.
8. Wilding JPH., et al. “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension”. Diabetes, Obesity and Metabolism 8 (2022): 1553-1564.
9. Cava E., et al. “Preserving healthy muscle during weight loss”. Advances in Nutrition3 (2017): 511-519.
10. Campos-Nonato I., et al. “Effect of a high-protein diet versus standard-protein diet on weight loss and biomarkers of metabolic syndrome: a randomized clinical trial”. Obesity Facts3 (2017): 238-251.
11. Treyzon L., et al. “A controlled trial of protein enrichment of meal replacements for weight reduction with retention of lean body mass”. Nutrition Journal1 (2008): 23.
12. Busetto L., et al. “Mechanisms of weight regain”. European Journal of Internal Medicine 93 (2021): 3-7.
13. Dulloo AG. “Physiology of weight regain: Lessons from the classic Minnesota Starvation Experiment on human body composition regulation”. Obesity ReviewsS2 (2021): e13189.
14. Aronne LJ., et al. “Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial”. JAMA1 (2024): 38-48.
15. Sooriyaarachchi P., et al. “Meal replacement as a weight loss strategy for night shift workers with obesity: a protocol for a randomized controlled trial”. Trials 1 (2022): 860.
16. Flechtner-Mors M., et al. “Metabolic and weight loss effects of long-term dietary intervention in obese patients: Four-year results”. Obesity Research5 (2000): 399-402.